BCL2 and neoplasm: Finally, simultaneous inhibition of Notch and Hh signaling sensitized prostate cancer tumor-initiating cells to docetaxel, a chemotherapy drug, by inhibiting AKT and downregulating the anti-apoptotic protein Bcl-2, highlighting the potential of targeting multiple pathways in CSC-driven cancers [194].